| Quarterly Financials | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 141 | 138 | 137 | 93 | 120 | 110 | 105 | 131 | 95 | 196 | 164 | 180 | 134 | 171 | 169 | 251 | 185 | 207 | 228 | 231 | 252 | 230 | 226 | 241 | 184 | 204 |
| Expenses | 148 | 133 | 129 | 108 | 100 | 91 | 108 | 123 | 95 | 116 | 151 | 154 | 119 | 147 | 146 | 177 | 161 | 175 | 185 | 188 | 212 | 192 | 191 | 210 | 159 | 195 |
| EBITDA | -7 | 6 | 7 | -15 | 21 | 19 | -3 | 8 | 0 | 79 | 13 | 26 | 15 | 24 | 23 | 74 | 24 | 32 | 43 | 42 | 40 | 38 | 35 | 32 | 26 | 9 |
| Operating Profit % | -9 % | -1 % | 0 % | -23 % | 16 % | 17 % | -5 % | -3 % | -3 % | 9 % | 7 % | 13 % | 10 % | 11 % | 9 % | 16 % | 12 % | 12 % | 16 % | 13 % | 13 % | 14 % | 12 % | 12 % | 8 % | -1 % |
| Depreciation | 31 | 32 | 32 | 23 | 30 | 30 | 29 | 20 | 20 | 20 | 20 | 27 | 22 | 18 | 8 | 7 | 8 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| Interest | 0 | 0 | 3 | 1 | 14 | 13 | 13 | 12 | 11 | 10 | 7 | 5 | 8 | 9 | 8 | 8 | 6 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 3 | 4 |
| Profit Before Tax | -39 | -26 | -28 | -39 | -23 | -24 | -45 | -25 | -31 | 49 | -14 | -6 | -14 | -3 | 7 | 59 | 11 | 20 | 30 | 30 | 28 | 26 | 23 | 19 | 14 | -3 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | -1 | 0 | 1 | 0 | 1 | -3 | -1 | -1 | 2 | -3 | -1 | 2 |
| Net Profit | -39 | -26 | -28 | -39 | -23 | -24 | -45 | -25 | -31 | 49 | -14 | -7 | -15 | -5 | 8 | 59 | 9 | 20 | 29 | 33 | 29 | 27 | 21 | 22 | 15 | -6 |
| EPS in ₹ | -4.32 | -2.93 | -3.11 | -9.52 | -5.55 | -5.98 | -10.96 | -6.06 | -7.57 | 12.10 | -3.40 | -1.61 | -3.68 | -1.32 | 1.86 | 14.49 | 1.85 | 4.30 | 6.18 | 6.81 | 5.79 | 5.37 | 4.10 | 4.40 | 2.94 | -1.13 |
Orchid Pharma
Orchid Pharma
857.30
-14.65
(-1.68%)
Market Cap
₹4,348.15 Cr
PE Ratio
84.36
Volume
78,986.00
Day High - Low
₹892.90 - ₹850.00
52W High-Low
₹1,997.40 - ₹603.80
Key Fundamentals
Market Cap
4,348.15 Cr
EPS
19.65
PB Ratio
3.46
Book Value
251.16
EBITDA
144.70
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.13
Analyst Rating and Forecast
- By Refinitiv from3 analysts
Actual
Company News
View All News
Orchid Pharma reported quarterly sales of INR 194 crores, down 13% year-on-year, with gross margins compressed to 32% from 43% due to inventory revaluation and weak antibiotic market conditions. The company completed acquisition of global rights to Enmetazobactam (Exblifep) and reported strong domestic performance with 15,000 patients treated and 200,000+ vials sold through its Orblicef brand partnership with Cipla.
Orchid Pharma Limited submitted its monitoring agency report for the quarter ended September 30, 2025, regarding the utilization of Rs. 400 crore raised through Qualified Institutional Placement. The company revised the allocation of QIP proceeds among project objectives following shareholder approval through AGM resolution dated September 20, 2025. Two key projects face implementation delays: the investment in Orchid BioPharma Limited for setting up manufacturing facility in Jammu, and funding capital expenditure for new API facility block in Alathur, Tamil Nadu, though the extent of delays remains unascertainable. For the Jammu project, Rs. 73.02 crores has been utilized as of September 30, 2025, with land acquisition challenges cited as the primary cause of delay. Registration of 164.50 Kanal out of 203.8 Kanal identified land has been completed, with remaining land registration expected by December 2025. The Alathur project delay is attributed to dependency on the Jammu 7ACA project, with only Rs. 0.36 crores utilized. The company has deployed unutilized proceeds in fixed deposits with Yes Bank Limited. CARE Ratings Limited served as the monitoring agency and reported no deviation from stated objectives.
Orchid Pharma Plans Capacity Expansion and New Product Launches with 13% Revenue Growth Target
Nov 11, 2025
Nov 11, 2025Orchid Pharma is targeting capacity expansion and new product launches across Cephalosporin and Carbapenem APIs. The company projects FY26 revenue growth of 13% year-on-year. A new plant in Chennai is being commissioned to enhance API output by 25%. The company is focusing on export market penetration and backward integration. The R&D pipeline includes 8 new molecules. Orchid Pharma expects volume-led growth and higher EBITDA margins in FY26-27.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,810.30 | #1 4,34,351.61 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 76.30 | |
6,490.50 | 1,72,302.38 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.50 | |
3,730.40 | 1,26,253.69 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 54.46 | |
1,525.20 | 1,23,198.65 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.61 | |
1,249.30 | 1,04,268.30 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 53.75 | |
2,071.40 | 94,612.13 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 63.44 | |
937.25 | 94,309.28 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 41.16 | |
2,249.30 | 92,841.77 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 38.34 | |
1,235.80 | 71,775.46 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 67.24 | |
5,686.50 | 67,990.64 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 53.98 |
Growth Rate
Revenue Growth
11.67 %
Net Income Growth
0.74 %
Cash Flow Change
-84.74 %
ROE
-7.01 %
ROCE
-6.21 %
EBITDA Margin (Avg.)
-8.47 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
| Fixed Assets | 1,795 | 1,637 | 1,497 | 1,386 | 1,256 | 858 | 670 | 584 | 573 | 620 | 633 |
| Current Assets | 1,278 | 1,251 | 675 | 679 | 768 | 569 | 550 | 398 | 501 | 791 | 807 |
| Capital Work in Progress | 282 | 280 | 288 | 272 | 278 | 26 | 7 | 10 | 47 | 31 | 81 |
| Investments | 0 | 0 | 1 | 1 | 1 | 0 | 15 | 46 | 44 | 46 | 50 |
| Other Assets | 1,985 | 1,945 | 1,470 | 1,467 | 1,542 | 576 | 544 | 472 | 561 | 857 | 925 |
| Total Liabilities | 4,061 | 3,862 | 3,256 | 3,125 | 3,077 | 1,460 | 1,237 | 1,111 | 1,225 | 1,554 | 1,688 |
| Current Liabilities | 1,123 | 1,338 | 1,510 | 2,013 | 2,346 | 175 | 142 | 241 | 372 | 260 | 286 |
| Non Current Liabilities | 2,609 | 2,475 | 2,212 | 1,905 | 1,436 | 519 | 442 | 222 | 165 | 124 | 135 |
| Total Equity | 329 | 49 | -467 | -792 | -704 | 766 | 653 | 647 | 689 | 1,170 | 1,267 |
| Reserve & Surplus | 244 | -40 | -556 | -881 | -793 | 725 | 544 | 538 | 579 | 1,050 | 1,148 |
| Share Capital | 85 | 89 | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 367 | -76 | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 18 |
| Investing Activities | 1,334 | -2 | -176 | -28 | 46 | 167 | 67 | 113 | -31 | -312 | -27 |
| Operating Activities | -369 | 212 | 401 | 9 | 12 | 81 | 24 | 93 | 18 | 126 | 19 |
| Financing Activities | -597 | -286 | -465 | 33 | -0 | -250 | -165 | -217 | 31 | 167 | 25 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 98.07 % | 90.00 % | 90.00 % | 90.00 % | 90.00 % | 89.96 % | 89.96 % | 89.96 % | 89.96 % | 72.40 % | 72.40 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % | 69.84 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 4.14 % | 1.96 % | 1.42 % | 1.94 % | 2.53 % | 2.69 % | 1.40 % | 1.56 % |
| DIIs | 1.00 % | 3.44 % | 3.35 % | 3.35 % | 2.97 % | 2.97 % | 2.98 % | 3.94 % | 2.62 % | 13.49 % | 9.88 % | 14.50 % | 17.73 % | 18.93 % | 18.29 % | 18.99 % | 20.10 % | 19.43 % | 19.04 % |
| Government | 0.00 % | 0.00 % | 0.04 % | 0.04 % | 0.04 % | 0.04 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.58 % | 2.34 % | 2.72 % | 2.83 % | 3.34 % | 3.69 % | 3.61 % | 3.44 % | 3.38 % | 3.10 % | 3.85 % | 7.79 % | 7.44 % | 7.16 % | 7.59 % | 6.42 % | 5.11 % | 6.91 % | 7.03 % |
| Others | 0.35 % | 4.22 % | 3.89 % | 3.79 % | 3.65 % | 3.34 % | 3.44 % | 2.66 % | 4.03 % | 11.02 % | 13.87 % | 3.74 % | 3.03 % | 2.65 % | 2.35 % | 2.22 % | 2.27 % | 2.43 % | 2.54 % |
| No of Share Holders | 30,343 | 33,379 | 34,798 | 33,535 | 33,698 | 33,679 | 32,717 | 30,894 | 29,523 | 29,039 | 29,197 | 36,931 | 36,720 | 34,695 | 36,363 | 34,158 | 34,303 | 39,827 | 38,155 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 Aug 2024 |  Annual General Meeting | NA | 21 Aug 2024 | 1,147.85 | 1,398.00 |
| 11 Nov 2024 |  Quarterly Result Announcement | NA | 11 Nov 2024 | 1,394.75 | 1,499.45 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,457.50 | 1,245.55 |
| 26 May 2025 | Quarterly Result Announcement | NA | 26 May 2025 | 759.20 | 754.40 |
| 26 Jun 2025 |  Extraordinary General Meeting | NA | 26 Jun 2025 | 669.00 | 701.95 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 800.85 | 780.15 |
| 20 Sept 2025 | Annual General Meeting | NA | 20 Sept 2025 | 780.15 | 788.55 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 789.30 | 846.25 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Monitoring Agency ReportNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2025
Nov 11, 2025Unaudited Limited Reviewed Financial Results For Q-2 Of F.Y.2025-26Nov 11, 2025
Nov 11, 2025Board Meeting Outcome for Outcome Of Board Meeting- Q2- F.Y.2025-26Nov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 05, 2025
Nov 05, 2025Board Meeting Intimation for Prior Intimation Of Board Meeting Scheduled To Be Held On November 11 2025
Nov 05, 2025
Nov 05, 2025Company Response On The Spurt In Volume Of Security Across ExchangesNov 04, 2025
Nov 04, 2025Clarification sought from Orchid Pharma LtdNov 04, 2025
Nov 04, 2025Update On Purchase Of Assets Of Allecra Therapeutics GmbhOct 30, 2025
Oct 30, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 10, 2025
Oct 10, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Meeting UpdatesSep 20, 2025
Sep 20, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 20, 2025
Sep 20, 2025Corrigendum To Notice Of 32Nd Annual General Meeting Of Orchid Pharma Limited (The Company) For The F.Y. 2024-25Sep 10, 2025
Sep 10, 2025CORRIGENDUM TO NOTICE OF 32ND ANNUAL GENERAL MEETINGSep 10, 2025
Sep 10, 2025Intimation Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited ( Amalgamating Company ) With Orchid Pharma Limited ( Amalgamated Company/Company )Aug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 27, 2025
Aug 27, 2025Reg. 34 (1) Annual Report.Aug 26, 2025
Aug 26, 2025Annual Report And Notice Of 32Nd Annual General Meeting Of Orchid Pharma Limited (The Company) For The F.Y. 2024-25Aug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 12, 2025
Aug 12, 2025Intimation Of Appointment Of Auditors Of The CompanyAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Aug 12, 2025Outcome Of Board Meeting Inter-Alia For Consideration And Approval Of Financial Results For The Q-1 Of F.Y.2025-26 Ended On June 30 2025Aug 12, 2025
Aug 12, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Credit RatingAug 07, 2025
Aug 07, 2025Update On Purchase Of Assets Of Allecra Therapeutics SASAug 05, 2025
Aug 05, 2025Board Meeting Intimation for Approval Of Unaudited Limited Reviewed Financial Results (Standalone & Consolidated) Of The Company For Quarter-1 Of F.Y.2025-26Aug 05, 2025
Aug 05, 2025Purchase Of Assets Of Allecra Therapeutics Gmbh
And Allecra Therapeutics SAS Related To Enmetazobactam.Jul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 30, 2025
Jul 30, 2025Intimation For Execution Of Deed Of Hypothecation In Favour Of HDFC Bank LimitedJul 17, 2025
Jul 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Intimation Related To The Scheme Of Amalgamation Of Dhanuka
Laboratories Limited (Amalgamating Company) With Orchid Pharma Limited (Amalgamated Company/Company) And Their Respective Shareholders And Creditors (The Scheme) Under Regulation 30 Of SEBI (LisJul 10, 2025
Jul 10, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Shareholder Meeting / Postal Ballot-Outcome of Court Convened MeetingJun 26, 2025
Jun 26, 2025Intimation Of Record Date For Voting Rights Of Shareholders W.R.T. The Meeting Of Equity Shareholders Of Orchid Pharma Limited ("Company"/ "Amalgamated Company") Convened Pursuant To The Order Passed By Honble National Company Law Tribunal For ConsideringJun 09, 2025
Jun 09, 2025Intimation Under Regulation 30 Of SEBI Listing Regulations- Honble National Company Law Tribunal Order To Dispose-Off Dispute On Lease Rentals With DBS Bank India Limited.Jun 06, 2025
Jun 06, 2025Disclosure Of Corporate Guarantee On Behalf Of Orchid Bio-Pharma Limited (Wholly Owned Subsidiary)Jun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 02, 2025
Jun 02, 2025Intimation On Receipt Of EIR After The USFDA Inspection At The Plant Of The Company Situated At AlathurMay 29, 2025
May 29, 2025Board Comments On Fine Levied By The ExchangeMay 28, 2025
May 28, 2025Mutual Fund Holdings
Invesco India Contra Fund Direct-Growth 
UTI ELSS Tax Saver Fund Direct-Growth 
ITI Value Fund Direct - Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Bandhan BSE Healthcare Index Fund Direct-Growth 
Kotak MNC Fund Direct-Growth 
JM Aggressive Hybrid Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 65.33
ATR(14)
Volatile 41.26
STOCH(9,6)
Neutral 76.21
STOCH RSI(14)
Oversold 15.18
MACD(12,26)
Bullish 2.19
ADX(14)
Weak Trend 19.51
UO(9)
Bearish 54.48
ROC(12)
Uptrend And Accelerating 3.34
WillR(14)
Overbought -15.62
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
